San Diego is known for its quiet ambition. Hundreds of small biotech companies operate in glass-fronted office parks behind the palm trees and unending sunshine, conducting clinical trials that most people will never learn about until all of a sudden everyone does. Among those businesses is Viking Therapeutics. It hardly made an impression on Wall Street for a very long time. It may now be impossible to ignore, depending on what transpires in the coming months.
VK2735, the company’s top drug candidate, is a GLP-1 receptor agonist that targets obesity, the same class of medication that nearly instantly made Novo Nordisk and Eli Lilly into major pharmaceutical companies. The financial community became aware of the potential size of this market when Ozempic became a cultural phenomenon and Zepbound began outselling it.
| Category | Details |
|---|---|
| Company Name | Viking Therapeutics, Inc. |
| Stock Ticker | VKTX (NASDAQ) |
| Sector | Biotechnology / Pharmaceuticals |
| Founded | 2012 |
| Headquarters | San Diego, California, USA |
| Market Cap | ~$4.0 Billion |
| Current Share Price | ~$34.80 (as of early April 2026) |
| 52-Week Range | $18.92 – $43.15 |
| Key Drug Candidate | VK2735 (GLP-1/GIP receptor agonist for obesity) |
| Trial Stage | Phase 3 (injectable); Phase 3 scheduled (oral) |
| Primary Competitors | Novo Nordisk (Wegovy), Eli Lilly (Zepbound) |
| Reference Website | Viking Therapeutics Official Site |
By the early 2030s, analysts predict that sales in the GLP-1 weight loss market could reach $100 billion annually. People tend to pay close attention to who else might be seated at the table when they see a number like that.
For some time now, Viking has been quietly seated at that table. It is noteworthy that phase 3 clinical trials are presently underway for the injectable form of VK2735. Phase 3 is a significant milestone in the biotech industry; most medications never reach that stage.
Investors who have been monitoring the data have expressed cautious but genuine optimism due to the truly encouraging early trial results. A phase 3 trial for the oral form is planned to start later this year. Even Novo Nordisk and Eli Lilly are still struggling to break into a market niche, but if the oral candidate succeeds—which is still a very big “if”—it might.
This asymmetry is difficult to ignore. At the moment, Viking’s market value is approximately $4 billion. For comparison, Eli Lilly is worth several hundred billion dollars. Theoretically, buyout offers could be two or three times the current valuation if VK2735 proves to be commercially viable and Viking becomes an acquisition target, a scenario that analysts are openly discussing.
At one point, the stock was trading close to $100 per share. It is currently about $34. What the trials reveal will determine whether that gap is a warning or an opportunity.
That’s the problem with biotech binary bets. A middle ground does not exist. The data is either reliable or unreliable. The stock quickly collapses along with VK2735’s commercial prospects if subsequent trial results are disappointing.
Viking shares were trading in the low single digits prior to Wall Street becoming interested in the GLP-1 excitement. When investors buy in today, they are implicitly accepting that a sharp decline is not only hypothetical but also feasible.
However, the benefits are just as real. Not only did Eli Lilly’s Zepbound surpass Wegovy in sales, but it also outperformed it due to stronger clinical evidence. Efficacy drives rapid adoption, as the weight loss industry has repeatedly demonstrated.
A large pharmaceutical company with billions to spend would most likely knock on VK2735’s door if it posts strong phase 3 numbers, which would make the commercial path forward much clearer. When it comes to acquisitions, big pharmaceutical companies are not sentimental. They adhere to the data.
Investors appear to think—or at least hope—that Viking will soon reach its own turning point. In fact, one of the more peculiar aspects of this particular speculative play is the comparatively short timeframe for significant trial outcomes.
The majority of biotech stories ask investors to wait years to find out if their risk was worthwhile. Viking might have the solution in a matter of months. Depending on your level of risk tolerance, that condensed timeline can be either comforting or frightening.
It is important to recognize the larger context. The GLP-1 area is becoming overcrowded. Pfizer is developing candidates. Roche is making investments. Amgen is competing. In an attempt to regain ground lost to Lilly, Novo Nordisk recently unveiled a more potent version of Wegovy, demonstrating that even the market leaders are not standing still.
A small business with a $4 billion market capitalization is attempting to make a name for itself in this fiercely competitive environment. That sounds intimidating. Additionally, it could be the exact type of underdog tale that occasionally yields remarkable returns on investment.
Even if the trials are successful, it’s still unclear if Viking can truly compete on a commercial level. Insurance negotiations, distribution networks, and manufacturing scale are all battles that cost billions of dollars. However, if the objective is an acquisition rather than a stand-alone commercial launch, that might not matter. After acquiring Viking, a massive pharmaceutical company would take over the medication and handle the logistics.
Viking Therapeutics is a calculated risk with a clear timeline for investors who are already at ease with speculative positions. It’s not certain. Not even near. However, there is something almost refreshing about a biotech story where the moment of truth is actually close in a market where most biotech stories are drawn out and ambiguous.